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Abstract
The preparation of alkyne-modified ansamitocins by mutasynthetic supplementation of Actinosynnema pretiosum mutants with
alkyne-substituted aminobenzoic acids is described. This modification paved the way to introduce a thiol linker by Huisgen-type
cycloaddition which can principally be utilized to create tumor targeting conjugates. In bioactivity tests, only those new ansami-
tocin derivatives showed strong antiproliferative activity that bear an ester side chain at C-3.
Introduction
Although natural products and analogues cover a large portion
of the drug market particularly in the treatment of cancer as
well as bacterial and viral infections their role in pharmaceu-
tical research has decreased over the past two decades. In part,
this development is due to their often limited accessibility as
well as their structural complexity. This situation hampers their
use as lead structures for which access to small compound
libraries is essential in order to perform structure–activity rela-
tionship studies. Besides semisynthetic and total synthesis
approaches the combination of chemical synthesis with biotech-
nological strategies has seen increased interest lately [1-3]. The
concepts either rely on a concise understanding of the biosyn-
thesis of natural products or simply individual enzymes for in
vitro applications [4]. In this context, producer strains that are
genetically engineered in the biosynthesis of important and
complex natural products have shown to be powerful synthetic
tools, e.g., knock out mutants are key players in mutational
biosynthesis, or in short mutasynthesis. This technique relies on
the cellular uptake of modified biosynthetic intermediates.
Processing of these intermediates, sometimes called mutasyn-
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Scheme 1: Short representation of ansamitocin biosynthesis.
thons, can provide complex secondary metabolites specifically
modified as planned by choice of the synthetic modification
incorporated into the mutasynthon [5-7].
In earlier work, we demonstrated that the ansamitocins
(maytansinoids) 3–5 are an ideal showcase for creating small
libraries by mutasynthesis [8-10]. These secondary metabolites
exert strong antiproliferative activity towards different leukemia
cell lines as well as human solid tumors. Inhibitory concentra-
tions were as low as 10−3 to 10−7 µg/mL [11] which resulted
from binding to β-tubulin monomers [12]. The ansamitocins are
produced by Actinosynnema pretiosum. For our mutasynthetic
studies we utilized an AHBA blocked mutant of A. pretiosum
[13-21]. 3-Amino-5-hydroxybenzoic acid (1, AHBA) is the
starter building block of the PKS type I that is responsible for
the biosynthesis of the ansamitocin backbone [22]. This PKS is
a well studied megaenzyme complex and after the action of
tailoring enzymes succeeding the PKS machinery ansamitocins
3–5 are formed [23-27].
In the present case, 1 is loaded on the starter module of the
polyketide synthase (Scheme 1). The last PKS module releases
and cyclizes seco-proansamitocin, likely by an ansamycin
amide synthase (gene asm9) [23-27], that generates the
19-membered macrocyclic lactam proansamitocin (2). From
here a set of tailoring enzymes transform proansamitocin into
the bioactive final metabolites 3–5 following a predetermined
logic that is only flexible in part (Scheme 1).
We extended these studies by combining mutasynthesis and
semisynthesis and thus accessed four new tumor specific folic
acid/ansamitocin conjugates [28] (Scheme 2). Bromo-ansami-
tocin 6 was obtained by mutasynthesis and was synthetically
modified to the complex folic acid/drug conjugate 7. The
vitamin folic acid has become a promising ligand for selec-
tively targeting the folate receptor (FR) in cancer tissues where
the FR is known to be overexpressed [29,30]. Folic acid has a
high affinity for the FR (Kd = 10−10 M), even when conjugated
to a cytotoxin such as maytansin. An important feature of these
conjugates is the linker concept that connects the drug to the
tumor-specific ligand. The linker is commonly designed in a
way that a release mechanism of the cytotoxin is part of the
molecular architecture of the conjugate [31].
Disulfide linkers have shown to be well suited when utilizing
the reducing power between extra- and intracellular milieus
which results in cleavage and liberation of the drug. Mitomycin
conjugates [32] were one of the earliest examples of folate
disulfide–drug conjugates and after the conjugate is internal-
ized by endocytosis, it was demonstrated that the endosomes
exert reductive cleavage.
For conjugate 7 we found that disulfide cleavage provided a
thiol derivative of ansamitocin P-3 (4, AP-3) 8 with still strong
antiproliferative activity (IC50 < 10 nM) for different cancer cell
lines. Importantly, the intact conjugate showed strong antipro-
liferative activity for a FR+ cancer cell line but was inactive
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Scheme 2: Structures of bromo-ansamitocin derivative 6, folate-ansamitocin P-3 conjugate 7 and thiol 8.
against a FR− cell line. Indeed, despite the substantial size of
the substituent remaining at C19 after reductive cleavage,
ansamitocin derivative 8 still showed sufficient antiprolif-
erative activity. This is in line with our observation that struc-
tural changes at the aromatic ring do not affect the biological
properties of the ansamitocins to a great extent [13-21].
In order to broaden the opportunities of this approach for the
ansamitocins, we now describe alternative accesses towards
disulfide linked conjugates that are based on thiol-functional-
ized AP-3 derivatives. These are planned to be obtained by a
combined muta- and semisynthetic strategy using different
aminobenzoic acids as mutasynthons.
Results and Discussion
Mutasynthetic experiments
As potential groups for introducing linker systems bound to the
aromatic moiety that contain terminal thiol groups (B and D,
Scheme 3), we envisaged several activated functional groups
(Hal, OH, NH2). Activation was planned to be achieved by
benzylic positioning as well as by choosing aryl bromides A
(Scheme 3) that can be modified to the corresponding aryl
alkynes C by cross coupling chemistry. Previously, we success-
fully utilized this combination of mutasynthesis and semisyn-
thesis for 19-brominated ansamitocin derivatives [13]. Alter-
natively, also alkyne-, vinyl- and allyl-substituted aminoben-
zoic acids can serve as mutasynthons so that the corresponding
alkynyl- or respectively alkenyl-substituted ansamitocin deriva-
tives can be accessed directly after fermentation. Alkynes can
be further used for Huisgen-type cycloadditions better known as
“copper mediated Click-chemistry” while alkenes, especially
vinyl- and allylbenzoic systems, are predestined for being
utilized in cross metathesis reactions.
Therefore a series of aminobenzoic acids 9–20 (Figure 1) were
prepared (see Supporting Information File 1). We expected
them to serve our purposes, when fully processed after being
fed to the mutant strain of A. pretiosum blocked in the
biosynthesis of the PKS starter unit AHBA (1). We found that
several of these aminobenzoic acids, namely 10, 14 and
16–20 were either not loaded onto the PKS or not processed
by the polyketide synthase in A. pretiosum and thus no forma-
tion of new ansamitocin derivatives was encountered in these
cases.
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Scheme 3: Strategies for introducing linker-based thiol groups to the aromatic moiety of ansamitocin P-3 for accessing tumor targeting conjugates
(CuAAC; Cu-mediated azide–alkyne cycloaddition).
Figure 1: m-Aminobenzoic acid derivatives 9–20 tested as mutasynthons.
In contrast, benzoic acid 11 provided Br-F-ansamitocin deriva-
tives 21a–d after being fed to a growing culture of the mutant
strain as judged by HRMS (Scheme 4). The retention times in
LC and MS experiments clearly showed common patterns for
ansamitocins. Additionally, the isotopic pattern provided evi-
dence for the incorporation of the bromo functionality (see
Supporting Information File 1). However, yields for each of the
four ansamitocins were too small for practical scale-up.
To evaluate the sterical and electronical properties of mutasyn-
thon 11 with respect to bioprocessing, 3-amino-5-bromoben-
zoic acid (9) was next employed in feeding experiments. It was
well processed to a series of new ansamitocin derivatives 22a–f
(Scheme 5).
Again, all derivatives showed common fragmentation patterns
and isotopic composition in the MS. Bromo-ansamitocin deriva-
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Scheme 4: Mutasynthetic transformation of aminobenzoic acid 11 with AHBA(−)-mutant of A. pretiosum; putative structures of ansamitocin-deriva-
tives 21a–d as judged from HRMS analysis.
Scheme 5: Mutasynthetic transformation of aminobenzoic acid 9 with AHBA(−)-mutant of A. pretiosum to bromo-ansamitocins 22a–f and detoxifica-
tion products 22g and 22h.
tives 22a, 22c and 22e were isolated after scale up to a 1000 mL
culture broth. Structures, expected from HRMS analysis, were
corroborated by NMR spectroscopy. Yields were determined to
be in the low mg/L range or 0.01% yield based on compound 9
(see Supporting Information File 1 for further details). In addi-
tion to the formation of the bromo-ansamitocin derivatives, also
the detoxification products 22g and 22h were isolated in 0.1%
yield. The bromo-ansamitocins can be regarded to be an ideal
starting material for transition metal-catalyzed coupling reac-
tions. Due to the low product yield obtained with mutasynthon
9, for which the steric demand of the bromo substituent can
likely be made responsible, we switched the strategy towards
the direct introduction of an alkyne moiety by a mutasynthetic
approach. Feeding of alkynyl(amino)benzoic acid 12 to cultures
of the AHBA(−)-mutant of A. pretiosum yielded six new
alkynyl-modified ansamitocin derivatives 23a–f in yields in the
lower mg/L range (Scheme 6). Among them, the major com-
pound 23f was obtained in 0.34% yield based on compound 12,
furnishing enough mutasynthetic material (15 mg) for further
chemical transformations (see below).
Likewise, also feeding of propargyl-substituted aminobenzoic
acid 13 furnished new propargyl-modified ansamitocins 24a–g.
Besides the expected AP-3 derivative 24a, also the formation of
the corresponding N-desmethyl ansamitocins 24b and 24c and/
or desepoxy-derivatives 24b–d were encountered. Finally, also
the propargyl-modified proansamitocin 24e and two truncated
derivatives 24f and 24g were obtained. We had observed this
unprecendeted defunctionalization at C7 in proansamitocin and
the possible biotransformation before for the mutasynthon
5-chloro-3-aminobenzoic acid [30]. Again, reduction of the keto
group at C9 occurred; but the relative configuration of C9 also
remains unknown in the present example. All derivatives, which
could be isolated in preparative scale (24b–d, 24f and 24g)
were formed in 0.1% scale.
In essence, the loading module of the ansamitocin PKS shows
excellent flexibility towards aminobenzoic acids that bear the
slim alkynyl or propargyl substituent at C5. After upscaling of
the fermentation alkynyl-ansamitocins 23c, 23f, 24b–d and 24f
and 24g were isolated and the structures were corroborated by
Beilstein J. Org. Chem. 2014, 10, 535–543.
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Scheme 6: Mutasynthetic transformation of aminobenzoic acids 12 and 13 with AHBA(−)-mutant of A. pretiosum.
analysis of NMR and MS spectra. Derivatives 23a, 23b, 23d,
23e and 24a, 24e were detected only by HRMS–MS analysis of
the crude extract.
Mutasynthetic experiments with vinyl(amino)benzoic acid 15
supposedly provided ansamitocin derivative 25 as judged by
HRMS–MS analysis of the crude extract (Scheme 7). However,
yields were too low for practical upscaling.
As mutasynthetic experiments with alkynyl- and propargyl-
(amino)benzoic acids gave best results, we decided to test the
Huisgen-type cycloaddition with alkynyl derivative 23f bearing
the biologically relevant ester side chain, the oxirane moiety
and the carbamoyl group for introducing a thiol moiety that
would be suited for further conjugation. Two linker elements
26a and 26b were prepared (see Supporting Information File 1)
and coupled with ansamitocin derivative 23f to yield the disul-
fide dimer 27a and the thioacetate 27c (Scheme 8). The former
could be transformed into the thiol monomer 27b by dithio-
threitol reduction.
Biological testing
New ansamitocin derivatives 22a, 22c, 22e, 23c, 23f, 24b–d,
24f, 24g, 27b and 27c were subjected to in vitro biological
testing with different human cell lines and one murine cell line
derived from tumors or from connective tissue, respectively.
The results are listed in Table 1 and are provided as values for
the half-maximal inhibitory concentration of the respective
ansamitocin derivatives. The most active derivatives were 23f
and 27c. Expectedly, 24b and 24f are inactive, as they lack the
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Scheme 7: Mutasynthetic transformation of vinyl(amino)benzoic acid 15 with AHBA(−)-mutant of A. pretiosum.
Scheme 8: Preparation of thiofunctionalized ansamitocin derivatives 27 by Huisgen-type copper-mediated cycloaddition.
Table 1: Antiproliferative activity IC50 [ng/mL] of 22a, 22c, 22e, 23c, 23f, 24b–d, 24f, 24g, 27b and 27c in comparison to AP-3 (4). Values shown are
means of two determinations in parallel; human cell lines: KB-3-1 (cervix carcinoma), A-431 (epidermoid carcinoma), SK-OV-3 (ovary adenocarci-
noma), PC-3 (prostate adenocarcinoma), L-929 (connective tissue of a mouse).
cell line KB-3-1 A-431 SK-OV-3 PC-3 L-929
compound
AP-3 4 0.11 0.050 0.030 0.035 0.1
22a 2.1 0.31 0.34 0.26 4.1
22c 0.28 0.65 3.1 4.0 78
22e 7.5 5.1 1.8 0.80 8.7
23c 2.2 0.77 0.46 0.28 1.9
23f 0.38 0.074 0.099 0.14 0.81
24b >10000 >10000 >10000 >10000 >10000
24c 7.8 5.5 9.0 18 220
24d 6.0 70 8.0 95 580
24f 1800 2200 2500 3500 >10000
24g 50 0.85 70 3.8 100
27b 2200 >10000 2800 >10000 >10000
27c 0.09 0.25 0.09 0.28 0.33
ester side chain at C3, the key pharmacophore of the maytansi-
noids. All other derivatives show strong to moderate antiprolif-
erative activity, irrespective whether the lack of the N-methyl
group, and or the oxirane groups or not. This is in line with the
view obtained from structure–activity relationship studies that
these tailoring modifications only modulate the biological
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activity of the maytansinoids. In the present study, the human
cancer cell lines were more sensitive than the mouse fibroblasts.
Some derivatives also seem to exert a specificity towards
certain cell lines, e.g. A-431 showed particular sensitivity for
24g.
The high antiproliferative activity of the “click” product 27c is
remarkable as it demonstrates that substantial structural changes
at C20 of the ansamitocins are tolerated and thus alkyne
substituents open up diverse opportunities to diversify that pos-
ition as reported including the introduction of tumor targeting
ligands. Noteworthy 27b is inactive which we ascribe to the fact
that it may have dimerized back to 27a.
Conclusion
The combination of mutasynthesis and semisynthesis has great
potential for the production of more selective ansamitocin
derivatives. In this work we pursued different options to prepare
ansamitocin derivatives by mutasynthesis that are set for intro-
ducing linker systems to the aromatic moiety suited to create
conjugates composed of ansamitocin and tumor-specific
ligands.
Supporting Information
The supporting information provide the synthesis of
building blocks, mutasynthetic experiments as well as
purification protocols after fermentations, a short
description of the cell proliferation assay, analytical
descriptions of new metabolites and copies of 1H and
13C NMR spectra.
Supporting Information File 1
Additional experimental details and NMR spectra.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-10-49-S1.pdf]
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